



BlueCross BlueShield of Louisiana

An independent licensee of the Blue Cross and Blue Shield Association.

Radioimmunoscintigraphy Imaging (Monoclonal Antibody Imaging) With Indium-111 Capromab Pendetide (ProstaScint®) for Prostate Cancer

Policy # 00419

Original Effective Date: 06/18/2014

Current Effective Date: 06/18/2014

Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc. (collectively referred to as the "Company"), unless otherwise provided in the applicable contract. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.

Services Are Considered Investigational

Coverage is not available for investigational medical treatments or procedures, drugs, devices or biological products.

Based on review of available data, the Company considers radioimmunoscintigraphy using indium-111 capromab pendetide (ProstaScint®)[†] to be **investigational.***

Background/Overview

Radioimmunoscintigraphy (RIS) involves the administration of radiolabeled monoclonal antibodies (MAbs), which are directed against specific molecular targets, followed by imaging with an external gamma camera. Indium-111 capromab pendetide is a monoclonal antibody directed against a binding site on prostate-specific antigen (PSA).

Radioimmunoscintigraphy is an imaging modality that uses radiolabeled MAbs to target specific tissue types. MAbs that react with specific cellular antigens are conjugated with a radiolabeled isotope. The labeled antibody-isotope conjugate is then injected into the patient and allowed to localize to the target over a 2- to 7-day period. The patient then undergoes imaging with a nuclear medicine gamma camera, and radioisotope counts are analyzed. Imaging can be performed with planar techniques or by using single-photon emission computed tomography (SPECT).

FDA or Other Governmental Regulatory Approval

U.S. Food and Drug Administration (FDA)

Indium-111 capromab pendetide (also referred to as CYT-356) targets an intracellular binding site on prostate-specific membrane antigen (PSMA) and has been approved by the FDA for use as a "diagnosing imaging agent in newly diagnosed patients with biopsy-proven prostate cancer, thought to be clinically localized after standard diagnostic evaluation, who are at risk for pelvic lymph node metastases and in postprostatectomy patients with a rising PSA and a negative or equivocal standard metastatic evaluation in whom there is a high clinical suspicion of occult metastatic disease." Other MAbs, directed at extracellular PSMA binding sites, are also under development.

Centers for Medicare and Medicaid Services (CMS)

No national guidelines or Medicare national coverage decisions (NCD) related to the use of indium-111 (In-111) capromab pendetide were identified. In the absence of an NCD, coverage decisions are left to the discretion of local Medicare carriers.



BlueCross BlueShield of Louisiana

An independent licensee of the Blue Cross and Blue Shield Association.

Radioimmunosintigraphy Imaging (Monoclonal Antibody Imaging) With Indium-111 Capromab Pendetide (ProstaScint[®]) for Prostate Cancer

Policy # 00419

Original Effective Date: 06/18/2014

Current Effective Date: 06/18/2014

Rationale/Source

This policy regarding the use of RIS in patients with prostate cancer is based on a 1998 Technology Evaluation Center (TEC) Assessment.

Radioimmunosintigraphy may be considered for use in a number of clinical indications. For the purposes of this policy, 2 main clinical situations will be considered:

- As part of the pretreatment workup for staging of prostate cancer. In this situation, the value of RIS is in detecting distant metastases that are not evident on other imaging studies, since detection of occult metastases is likely to alter treatment recommendations.
- In patients who have received curative treatment, but present with biochemical failure, ie, a rising PSA without definite disease on standard imaging studies. In this situation, differentiating between local and distant recurrence is important because local recurrence may be treated with salvage radiotherapy, while distant recurrence is usually treated with androgen deprivation therapy.

Pretreatment staging prior to curative treatment

Based on the 1998 TEC Assessment of RIS, sensitivity in detecting tumor in the pelvic lymph nodes ranged from 50% to 75% and specificity ranged from 72% to 92.6%. Pooled data from the studies reviewed in the TEC Assessment produced an estimated 61% positive predictive value (PPV). If positive RIS results were used to exclude a patient from receiving potentially curative therapy (ie, radical prostatectomy), then 38% of patients might be harmed by inappropriately withholding the potentially curative treatment. A pooled negative predictive value (NPP) of 73% suggests that if RIS played a key role in determining that pelvic lymph nodes were clear of tumor prior to radical prostatectomy, then 26.7% of patients with a negative RIS scan and truly positive lymph nodes might receive potentially ineffective surgery. In addition, there is debate over a potential survival benefit with performing prostatectomy in the setting of positive lymph nodes. Nevertheless, in terms of evaluating the pelvic nodes, the PPVs and NPVs are not sufficiently high enough to avoid pelvic lymph node dissection when necessary to determine patient management.

Since the 1998 TEC Assessment, several reports have been published that address the role of RIS in evaluating pelvic lymph node staging. However, several of the authors of these reports appear in multiple new and prior publications, and it seems possible that some of these populations overlap with previously reported results derived from multicenter studies. Moreover, the diagnostic accuracy of RIS for evaluating pelvic lymph nodes does not appear to be substantially improved in later reports.

Several of these reports use predictive modeling or cross-sectional correlation analysis to explore the value of RIS results in predicting the extent of disease in comparison with other factors such as PSA level, Gleason score, and clinical stage of disease.

In 2011, Reiter et al published a retrospective review of 197 patients who had both RIS and histopathology available at 1 institution over a 4-month period. For the lymph nodes, the sensitivity of RIS was 60.0% (95% confidence interval [CI], 14.7% to 94.7%) and the specificity was 97.4% (95% CI, 92.3% to 100%). The area under the curve by receiver operating characteristic (ROC) analysis was 78.7%. Increasing Gleason score was predictive of a positive RIS scan, as was the setting of a pretreatment evaluation.

©2014 Blue Cross and Blue Shield of Louisiana

An independent licensee of the Blue Cross and Blue Shield Association

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



BlueCross BlueShield of Louisiana

An independent licensee of the Blue Cross and Blue Shield Association.

Radioimmunoscintigraphy Imaging (Monoclonal Antibody Imaging) With Indium-111 Capromab Pendetide (ProstaScint[®]) for Prostate Cancer

Policy # 00419

Original Effective Date: 06/18/2014

Current Effective Date: 06/18/2014

These analyses suggest that RIS provides additional and independent information that correlates with extent of disease; however, the conclusions of these studies are derived from relationships across populations and do not directly translate into how RIS results would actually be used to guide management in a manner that would improve net health outcome. Without an understanding of diagnostic accuracy and how results would influence management, it is not possible to model potential effects on health outcomes. Thus, none of the reports identified in the update support the clinical effectiveness of using RIS to evaluate pelvic lymph nodes.

Evaluating patients with biochemical failure following prostatectomy or radiotherapy

Patients who experience a rising PSA following curative treatment for prostate cancer are considered to have a recurrence; however, the location of the recurrence is sometimes not evident for a period of time after biochemical failure. Localized recurrence is typically treated with salvage radiotherapy, whereas distant recurrence, ie, metastatic disease, is usually treated with androgen deprivation therapy.

In terms of evaluating recurrent or residual disease, there are limited data showing that the use of RIS in this patient group can detect additional sites of disease and would result in different management decisions compared to decisions based on usual care. Imaging evaluation may be useful in suspected recurrence due to rising PSA to localize recurrent tumor and to determine whether recurrent tumor is local to the prostate area, involves distant sites, or both. When residual or recurrent disease is only local, patients may undergo postoperative radiation therapy (RT), whereas, when the recurrence includes distant sites, hormonal therapy would be considered. Distant hematogenous metastasis from prostate cancer most frequently involves bone but can infrequently involve other soft tissue sites. Bone scan is generally considered to be more sensitive than RIS for detecting bone metastases. Positive RIS findings have been reported anecdotally in abnormalities other than prostate cancer, so biopsy confirmation of unexpected distant findings may be necessary to ensure proper patient management.

The available studies are generally retrospective, descriptive reports of patterns of RIS uptake in patients with suspected recurrence. These studies, however, do not provide consistent verification of disease status, and thus the rate of false positive and false negative RIS studies is not well-established. While some studies report what percent of cases had associated changes in management, it is frequently difficult to specifically determine how RIS results affected management and to determine whether these changes resulted in an improvement in net health outcome.

A retrospective study by Raj et al included 252 patients with biochemical failure following radical prostatectomy (PSA \leq 0.4 ng/mL) who had RIS performed to localize recurrence. In this study, 72% of subjects had a positive scan. A localized (prostatic fossa only) uptake pattern was seen in 30.6%, regional uptake pattern (regional lymph nodes plus or minus prostatic fossa and no distant disease) in 42.8%, and distant uptake noted in 29.4%. This study did not report the proportion of subjects in whom patient management was altered by RIS findings. Only a minority of patients (<20%) had also received a computed tomography (CT) scan or bone scan showing positive findings, making comparisons across technologies subject to potential bias. A uniform reference standard was not applied in this study, and detailed follow-up was available for only approximately half of the patients (132 of 255). The study reports sensitivity and

©2014 Blue Cross and Blue Shield of Louisiana

An independent licensee of the Blue Cross and Blue Shield Association

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



BlueCross BlueShield of Louisiana

An independent licensee of the Blue Cross and Blue Shield Association.

Radioimmunoscintigraphy Imaging (Monoclonal Antibody Imaging) With Indium-111 Capromab Pendetide (ProstaScint[®]) for Prostate Cancer

Policy # 00419

Original Effective Date: 06/18/2014

Current Effective Date: 06/18/2014

specificity in a small subset of subjects (ie, 95 of 252 total or 38% of subjects) who had some degree of verification of disease status. Reported sensitivity was 73% and specificity was 53%. However, due to the selected nature of the small subset analysis, these estimates are subject to potential verification bias and may not be considered valid measures of expected performance.

Sodee et al performed a retrospective analysis on a large multicenter study including 2290 RIS scans in 2154 patients with prostate cancer, either before or after treatment. This study reports the rates of positive RIS scans in local, regional, and distant sites but does not provide detailed verification of results and thus, sensitivity and specificity cannot be determined. When analysis was stratified by whether primary treatment had been surgery, radiation, or hormonal therapy, RIS showed uptake limited to extrapelvic nodes in 8.5% to 15.1% of patients and uptake in both pelvic and extrapelvic nodes in 22.1% to 33.2% of patients. Relatively few patients had also undergone CT scanning (n=146). When CT was compared with RIS, CT did not detect pelvic or extrapelvic nodes that were detected by RIS in 73% of CT cases. In contrast, in a separate study of 45 subjects, RIS did not perform as well as CT in detecting metastatic disease.

Kahn et al reported results in 32 patients who received salvage pelvic radiation for suspected recurrence and had received RIS imaging. The authors reported that RIS had 50% sensitivity, 89% specificity, 78% PPV, and 70% NPV for detecting patients who would develop tumor recurrence after irradiation. Thomas et al reported on the results of RIS in a case series of 30 men with recurrent prostate cancer treated with RT. This study found no correlation between the results of RIS and tumor control, as assessed by serial PSA levels. Further studies would be necessary to demonstrate that long-term outcomes after RT are improved when RIS is used to select patients.

Liauw et al reported on 82 patients with adenocarcinoma of the prostate treated with salvage RT for an elevated PSA level after prostatectomy. The median pre-RT PSA level was 0.63 ng/mL. Of the 82 patients, 47 (57%) had a pre-RT RIS ProstaScint scan, which was used for both patient selection and target delineation. Patients with a pre-RT RIS scan had a lower preoperative PSA level ($p=0.024$) and shorter follow-up ($p=0.022$) than those without RIS. With a median follow-up of 44 months, the biochemical control rate was 56% at 3 years and 48% at 5 years. Margin status was the only factor associated with biochemical control on univariate ($p=0.005$) and multivariate ($p=0.004$) analysis. Patients who had prostate bed-only uptake on RIS (n=38) did not have improved outcomes, with biochemical control rates of 51% at 3 years and 40% at 5 years. These data support the conclusion that patients who were selected for treatment with RIS did not have better biochemical outcomes.

Nagda et al reported on a series of 58 patients who had ProstaScint scans as part of an assessment of rising PSA after prostatectomy who were then treated with prostate bed RT. The 4-year biochemical relapse-free survival (BRFS) rates for patients with negative ProstaScint scans (53%), positive in the prostate bed alone (45%), or positive elsewhere (74%) scan findings did not differ significantly ($p=0.51$). The capromab pendetide scan status had no effect on BRFS. Those with a pre-RT PSA level of less than 1 ng/mL had improved BRFS ($p=.003$). The authors concluded that the capromab pendetide scan has a low PPV in patients with positive elsewhere uptake and the 4-year BRFS was similar to that for those who did not exhibit positive elsewhere uptake.



BlueCross BlueShield of Louisiana

An independent licensee of the Blue Cross and Blue Shield Association.

Radioimmunoscintigraphy Imaging (Monoclonal Antibody Imaging) With Indium-111 Capromab Pendetide (ProstaScint[®]) for Prostate Cancer

Policy # 00419

Original Effective Date: 06/18/2014

Current Effective Date: 06/18/2014

Proano et al reported "early experience" on outcomes among a group of 44 patients with biochemical recurrence after radical prostatectomy who underwent a ProstaScint scan immediately before salvage radiotherapy. They noted an improved prognosis (mean follow-up, 22 months) in patients who had a negative preradiotherapy scan but also noted that this finding was not necessarily independent of preradiotherapy PSA level.

Two publications raise questions about the accuracy (including sensitivity and specificity) of immunoscintigraphy, coregistered with CT, in imaging localized prostate cancer within the prostate gland and in detecting seminal vesicle invasion. In a prospective evaluation of 93 patients with recurrent prostate cancer, Schuster et al reported positron-emission tomography (PET)-CT with the radiotracer anti-1-amino-3-[(18)Fluorocyclobutane-1-carboxylic acid was significantly better in detecting prostatic and extraprostatic prostate cancer recurrence than RIS SPECT-CT imaging.

Use of RIS scanning to direct "image-guided" radiotherapy

One trial was identified that used the results of ProstaScint to change management. Wong et al prospectively enrolled 71 patients with localized prostate cancer and performed capromab pendetide scans on all prior to initiating intensity-modulated radiation therapy (IMRT) treatment. Areas of increased uptake within the prostate gland on RIS scanning were given an additional "boost" of radiation in addition to the baseline dose given to the entire gland. Grade 2 urinary and gastrointestinal toxicity was common, affecting up to 50% of patients, but grade 3 or higher toxicity was less frequent, with 4% of patients exhibiting grade 2 urinary toxicity. At a median of 66 months' follow-up, biochemical control was 94%. No attempt was made in this study to compare outcomes of "image-guided" IMRT with standard treatment.

Ongoing Clinical Trials

A search of online site ClinicalTrials.gov on December 15, 2013 identified no ongoing trials of ProstaScint or RIS and prostate.

Summary

Radioimmunoscintigraphy imaging with Indium -111 (In-111) capromab pendetide is an alternative imaging modality for patients with prostate cancer that is intended to assist in determining the extent and location of disease. For determining whether disease is present in the lymph nodes, RIS has a modest sensitivity, estimated at 50% to 75% and a moderate to high specificity, estimated at 72% to 93%. Because other imaging modalities have a suboptimal sensitivity for disease in the lymph nodes, RIS has been proposed to be used for staging prior to curative treatment. However, no studies have demonstrated that use of RIS for this purpose changes management, and therefore the evidence is insufficient to determine whether RIS improves health outcomes when used to stage prostate cancer pretreatment.

For patients with biochemical failure following curative treatment, RIS has been proposed to help differentiate between local and distant recurrence. There are numerous small case series that evaluate RIS in this population, and describe rates of positivity for local and distant disease. However, none of these studies demonstrate a change in management as a result of RIS. As a result, it is not possible to determine



BlueCross BlueShield of Louisiana

An independent licensee of the Blue Cross and Blue Shield Association.

Radioimmunoscintigraphy Imaging (Monoclonal Antibody Imaging) With Indium-111 Capromab Pendetide (ProstaScint[®]) for Prostate Cancer

Policy # 00419

Original Effective Date: 06/18/2014

Current Effective Date: 06/18/2014

whether use of RIS in this population improves outcomes. For the above reasons, RIS with In-111 capromab pendetide is considered investigational.

References

1. Blue Cross and Blue Shield Association, Medical Policy Reference Manual, "Radioimmunoscintigraphy Imaging (Monoclonal Antibody Imaging) With Indium-111 Capromab Pendetide (ProstaScint[®]) for Prostate Cancer", 6.01.37, 1:2014.
2. Blue Cross and Blue Shield Association. Technology Evaluation Center (TEC). Radioimmunoscintigraphy for Prostate Cancer – Update. TEC Assessments 1998; Volume 13, Tab 21.
3. Lange PH. PROSTASCINT scan for staging prostate cancer. *Urology* 2001; 57(3):402-6.
4. Moul JW, Kane CJ, Malkowicz SB. The role of imaging studies and molecular markers for selecting candidates for radical prostatectomy. *Urol Clin North Am* 2001; 28(3):459-72.
5. Lau HY, Kindrachuk G, Carter M et al. Surgical confirmation of ProstaScint abnormalities in two patients with high risk prostate cancer. *Can J Urol* 2001; 8(1):1199-202.
6. Manyak MJ, Hinkle GH, Olsen JO et al. Immunoscintigraphy with indium-111-capromab pendetide: evaluation before definitive therapy in patients with prostate cancer. *Urology* 1999; 54(6):1058-63.
7. Murphy GP, Snow PB, Brandt J et al. Evaluation of prostate cancer patients receiving multiple staging tests, including ProstaScint scintiscans. *Prostate* 2000; 42(2):145-9.
8. Polascik TJ, Manyak MJ, Haseman MK et al. Comparison of clinical staging algorithms and 111indium-capromab pendetide immunoscintigraphy in the prediction of lymph node involvement in high risk prostate carcinoma patients. *Cancer* 1999; 85(7):1586-92.
9. Quintana JC, Blend MJ. The dual-isotope ProstaScint imaging procedure: clinical experience and staging results in 145 patients. *Clin Nucl Med* 2000; 25(1):33-40.
10. Rosenthal SA, Haseman MK, Polascik TJ. Utility of capromab pendetide (ProstaScint) imaging in the management of prostate cancer. *Tech Urol* 2001; 7(1):27-37.
11. Sodee DB, Malguria N, Faulhaber P et al. Multicenter ProstaScint imaging findings in 2154 patients with prostate cancer. The ProstaScint Imaging Centers. *Urology* 2000; 56(6):988-93.
12. Rieter WJ, Keane TE, Ahlman MA et al. Diagnostic performance of In-111 capromab pendetide SPECT/CT in localized and metastatic prostate cancer. *Clin Nucl Med* 2011; 36(10):872-8.
13. Elgamal AA, Troychak MJ, Murphy GP. ProstaScint scan may enhance identification of prostate cancer recurrences after prostatectomy, radiation, or hormone therapy: analysis of 136 scans of 100 patients. *Prostate* 1998; 37(4):261-9.
14. Kahn D, Williams RD, Haseman MK et al. Radioimmunoscintigraphy with In-111-labeled capromab pendetide predicts prostate cancer response to salvage radiotherapy after failed radical prostatectomy. *J Clin Oncol* 1998; 16(1):284-9.
15. Murphy GP, Elgamal AA, Troychak MJ et al. Follow-up ProstaScint scans verify detection of occult soft-tissue recurrence after failure of primary prostate cancer therapy. *Prostate* 2000; 42(4):315-7.
16. Petronis JD, Regan F, Lin K. Indium-111 capromab pendetide (ProstaScint) imaging to detect recurrent and metastatic prostate cancer. *Clin Nucl Med* 1998; 23(10):672-7.
17. Raj GV, Partin AW, Polascik TJ. Clinical utility of indium 111-capromab pendetide immunoscintigraphy in the detection of early, recurrent prostate carcinoma after radical prostatectomy. *Cancer* 2002; 94(4):987-96.
18. Seltzer MA, Barbaric Z, Belldegrun A et al. Comparison of helical computerized tomography, positron emission tomography and monoclonal antibody scans for evaluation of lymph node metastases in patients with prostate specific antigen relapse after treatment for localized prostate cancer. *J Urol* 1999; 162(4):1322-8.
19. Khan A, Caride VJ. Indium-111 capromab pendetide (ProstaScint) uptake in neurofibromatosis. *Urology* 2000; 56(1):154.
20. Michaels EK, Blend M, Quintana JC. 111Indium-capromab pendetide unexpectedly localizes to renal cell carcinoma. *J Urol* 1999; 161(2):597-8.
21. Scott DL, Halkar RK, Fischer A et al. False-positive 111 indium capromab pendetide scan due to benign myelolipoma. *J Urol* 2001; 165(3):910-1.
22. Thomas CT, Bradshaw PT, Pollock BH et al. Indium-111-capromab pendetide radioimmunoscintigraphy and prognosis for durable biochemical response to salvage radiation therapy in men after failed prostatectomy. *J Clin Oncol* 2003; 21(9):1715-21.
23. Liauw SL, Weichselbaum RR, Zagaja GP et al. Salvage radiotherapy after postprostatectomy biochemical failure: does pretreatment radioimmunoscintigraphy help select patients with locally confined disease? *Int J Radiat Oncol Biol Phys* 2008; 71(5):1316-21.



BlueCross BlueShield of Louisiana

An independent licensee of the Blue Cross and Blue Shield Association.

Radioimmunoscintigraphy Imaging (Monoclonal Antibody Imaging) With Indium-111 Capromab Pendetide (ProstaScint[®]) for Prostate Cancer

Policy # 00419

Original Effective Date: 06/18/2014

Current Effective Date: 06/18/2014

24. Nagda SN, Mohideen N, Lo SS et al. Long-term follow-up of 111In-capromab pendetide (ProstaScint) scan as pretreatment assessment in patients who undergo salvage radiotherapy for rising prostate-specific antigen after radical prostatectomy for prostate cancer. *Int J Radiat Oncol Biol Phys* 2007; 67(3):834-40.
25. Proano JM, Sodee DB, Resnick MI et al. The impact of a negative (111)indium-capromab pendetide scan before salvage radiotherapy. *J Urol* 2006; 175(5):1668-72.
26. Mouraviev V, Madden JF, Broadwater G et al. Use of 111In-capromab pendetide immunoscintigraphy to image localized prostate cancer foci within the prostate gland. *J Urol* 2009; 182(3):938-47.
27. Tsivian M, Wright T, Price M et al. 111-In-capromab pendetide imaging using hybrid-gamma camera-computer tomography technology is not reliable in detecting seminal vesicle invasion in patients with prostate cancer. *Urol Oncol* 2012; 30(2):150-4.
28. Schuster DM, Nieh PT, Jani AB et al. Anti-3-[18F]FACBC PET-CT and 111In-capromab-pendetide SPECT-CT in Recurrent Prostate Carcinoma: Results of a Prospective Clinical Trial. *J Urol* 2013.
29. Wong WW, Schild SE, Vora SA et al. Image-guided radiotherapy for prostate cancer: a prospective trial of concomitant boost using indium-111-capromab pendetide (ProstaScint) imaging. *Int J Radiat Oncol Biol Phys* 2011; 81(4):e423-9.

Coding

The five character codes included in the Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines are obtained from Current Procedural Terminology (CPT[®])[‡], copyright 2013 by the American Medical Association (AMA). CPT is developed by the AMA as a listing of descriptive terms and five character identifying codes and modifiers for reporting medical services and procedures performed by physician.

The responsibility for the content of Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines is with Blue Cross and Blue Shield of Louisiana and no endorsement by the AMA is intended or should be implied. The AMA disclaims responsibility for any consequences or liability attributable or related to any use, nonuse or interpretation of information contained in Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein. Any use of CPT outside of Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines should refer to the most current Current Procedural Terminology which contains the complete and most current listing of CPT codes and descriptive terms. Applicable FARS/DFARS apply.

CPT is a registered trademark of the American Medical Association.

Codes used to identify services associated with this policy may include (but may not be limited to) the following:

Code Type	Code
CPT	78800, 78801, 78802, 78803, 78804
HCPCS	A9507
ICD-9 Diagnosis	185, V10.46
ICD-9 Procedure	92.16, 92.18, 92.19

Policy History

Original Effective Date: 06/18/2014

Current Effective Date: 06/18/2014

06/05/2014 Medical Policy Committee review

06/18/2014 Medical Policy Implementation Committee approval. New policy.

Next Scheduled Review Date: 06/2015

©2014 Blue Cross and Blue Shield of Louisiana

An independent licensee of the Blue Cross and Blue Shield Association

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



BlueCross BlueShield of Louisiana

An independent licensee of the Blue Cross and Blue Shield Association.

Radioimmunoscintigraphy Imaging (Monoclonal Antibody Imaging) With Indium-111 Capromab Pendetide (ProstaScint[®]) for Prostate Cancer

Policy # 00419

Original Effective Date: 06/18/2014

Current Effective Date: 06/18/2014

*Investigational – A medical treatment, procedure, drug, device, or biological product is Investigational if the effectiveness has not been clearly tested and it has not been incorporated into standard medical practice. Any determination we make that a medical treatment, procedure, drug, device, or biological product is Investigational will be based on a consideration of the following:

- A. whether the medical treatment, procedure, drug, device, or biological product can be lawfully marketed without approval of the U.S. Food and Drug Administration (FDA) and whether such approval has been granted at the time the medical treatment, procedure, drug, device, or biological product is sought to be furnished; or
- B. whether the medical treatment, procedure, drug, device, or biological product requires further studies or clinical trials to determine its maximum tolerated dose, toxicity, safety, effectiveness, or effectiveness as compared with the standard means of treatment or diagnosis, must improve health outcomes, according to the consensus of opinion among experts as shown by reliable evidence, including:
 - 1. Consultation with the Blue Cross and Blue Shield Association technology assessment program (TEC) or other nonaffiliated technology evaluation center(s);
 - 2. credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community; or
 - 3. reference to federal regulations.

‡ Indicated trademarks are the registered trademarks of their respective owners.

NOTICE: Medical Policies are scientific based opinions, provided solely for coverage and informational purposes. Medical Policies should not be construed to suggest that the Company recommends, advocates, requires, encourages, or discourages any particular treatment, procedure, or service, or any particular course of treatment, procedure, or service.